Cereno Scientific (CRNO) Q3 2024 earnings summary

Executive summary

• Positive topline results from Phase IIa trial of CS1 in PAH, showing safety, tolerability, and efficacy; preparations for Phase IIb/III underway.

• CS1 granted Orphan Medicinal Product Designation in the EU, securing 10-year market exclusivity post-authorization.

• CS014 advanced to Phase I MAD stage; IPF selected as initial target indication, reinforcing rare disease focus.

• Preclinical CS585 demonstrated sustained inhibition of platelet activation and clot formation; patent protection expanded to China.

• Secured minimum 250 MSEK loan financing, extending financial runway into 2026.

Financial highlights

• Net loss for Q3 2024 was SEK -22.7 million, compared to SEK -11.1 million in Q3 2023.

• Net loss for Jan–Sept 2024 was SEK -59.2 million, compared to SEK -26.2 million for Jan–Sept 2023.

• Cash and bank balances at period end were SEK 73.8 million, up from SEK 68.5 million a year earlier.

• Equity/assets ratio decreased to 66.8% from 95.4% year-over-year.

• Capitalized development expenditures increased to SEK 251.8 million from SEK 165.3 million year-over-year.

Outlook and guidance

• Financial runway secured into 2026, enabling pursuit of key milestones and strategic partnerships.

• Phase IIb/III trial for CS1 in PAH planned to initiate in 2026; regulatory discussions and EAP patient recruitment ongoing.

• CS014 Phase I trial to conclude by mid-2025, with Phase II start targeted for 2026.

• Business development and partnering activities to be intensified following recent data and financing.